RayzeBio Investor Relations Material
Latest events
Q3 2023
13 Nov, 2023
Corporate Presentation
12 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from RayzeBio Inc
Access all reports
RayzeBio Inc is a biotechnology firm concentrated on developing radiopharmaceutical therapeutics (RPT) for cancer treatment. Their leading drug candidate, RYZ101, is in clinical trials aimed at treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Additionally, RayzeBio is working on RYZ801, a novel proprietary peptide targeting GPC3 for the treatment of hepatocellular carcinoma (HCC), among other innovative drug candidates targeting various cancers. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
RYZB
Country
🇺🇸 United States